Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
AVI Japan Opportunity Trust Joe Bauernfreund | “Eiken Chemical ('Eiken') was the largest detractor, reducing -128bps as its share price returned -15%. Eiken is a clinical diagnostics manufacturer with strengths in faecal immunochemical testing, gastrointestinal diagnostics and molecular diagnostic technologies. The company has a solid position in niche diagnostic markets and owns valuable technology. An engagement fund submitted shareholder proposals to nominate two director candidates to the board. At the AGM held on 23 June, the proposals were rejected, despite receiving 45.75% support. The result led to a sharp share price decline following the AGM, particularly as investors who may have expected the proposals to pass or lead to more immediate governance change reduced their positions. The share price weakness was primarily driven by disappointment among short-term shareholders, rather than any deterioration in Eiken's underlying business fundamentals. The 45.75% support level was nevertheless significant, and this indicates that a substantial minority of shareholders continue to support change at the company. AVI remains constructive on Eiken's long-term prospects and believes the result should continue to place pressure on the board to improve governance, capital allocation and shareholder communication. Added to the portfolio in July 2023, Eiken now represents 7.0% of NAV. The investment has generated an ROI of +41% and an IRR of +22% in JPY.” | NEUTRAL | Q2 2026 Jul 17, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
